- Home
- RRR vs FOLD Comparison
RRR vs FOLD Comparison
Compare RRR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RRR
- FOLD
- Stock Information
- Founded
- RRR 1976
- FOLD 2002
- Country
- RRR United States
- FOLD United States
- Employees
- RRR N/A
- FOLD N/A
- Industry
- RRR Hotels/Resorts
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- RRR Consumer Discretionary
- FOLD Health Care
- Exchange
- RRR Nasdaq
- FOLD Nasdaq
- Market Cap
- RRR 2.6B
- FOLD 2.9B
- IPO Year
- RRR 2016
- FOLD 2007
- Fundamental
- Price
- RRR $60.54
- FOLD $6.32
- Analyst Decision
- RRR Buy
- FOLD Strong Buy
- Analyst Count
- RRR 12
- FOLD 10
- Target Price
- RRR $59.83
- FOLD $26.89
- AVG Volume (30 Days)
- RRR 910.1K
- FOLD 4.2M
- Earning Date
- RRR 07-29-2025
- FOLD 07-31-2025
- Dividend Yield
- RRR 8.26%
- FOLD N/A
- EPS Growth
- RRR 3.50
- FOLD N/A
- EPS
- RRR 2.93
- FOLD N/A
- Revenue
- RRR $1,987,845,000.00
- FOLD $571,160,000.00
- Revenue This Year
- RRR $1.24
- FOLD $19.97
- Revenue Next Year
- RRR $2.80
- FOLD $22.92
- P/E Ratio
- RRR $20.66
- FOLD N/A
- Revenue Growth
- RRR 7.47
- FOLD 32.29
- 52 Week Low
- RRR $35.09
- FOLD $5.51
- 52 Week High
- RRR $62.00
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- RRR 70.66
- FOLD 55.44
- Support Level
- RRR $54.13
- FOLD $6.06
- Resistance Level
- RRR $62.00
- FOLD $6.40
- Average True Range (ATR)
- RRR 1.72
- FOLD 0.28
- MACD
- RRR 0.45
- FOLD 0.01
- Stochastic Oscillator
- RRR 84.22
- FOLD 49.44
About RRR Red Rock Resorts Inc.
Red Rock Resorts Inc along with its subsidiary is a gaming, development and management company that develops and operates strategically-located casino and entertainment properties. Its casino properties are conveniently located throughout the Las Vegas valley and provide its customers a wide variety of entertainment and dining options. The majority of revenue is derived from Casinos.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.